Eric Valeur, Ph.D.

Vice President, Head of Drug Discovery

Portrait of Eric Valeur

Eric has more than 15 years drug discovery experience gained at small, mid-size and large pharma/biotech companies including Merck-Serono, Novartis, and AstraZeneca.

His experience spans several therapeutic areas and drug modalities, including small molecules, macrocycles, peptides, oligonucleotides, drug conjugates, and degraders, with a track record of delivering across discovery phases, including clinical candidates and novel technologies. At AstraZeneca, he built the first New Modalities group in the industry, which paved the way for the rapid expansion of the field, later fueled by protein degradation approaches. There, he also led a corporate-wide drug discovery transformation project, which brought large investments into multiple areas including the use of AI for drug discovery. Before joining Roivant, he built a first-in-category biotech company at Flagship Pioneering, leading the R&D team from inception, and demonstrated proof-of-concept for a new modality.

Eric is coauthor/coinventor of over 65 publications, patents, posters and oral presentations. He holds a doctor of philosophy degree in organic chemistry from the University of Edinburgh in Edinburgh and a master’s of business administration from Imperial College London in London.

Follow Eric: